Welcome to the BioLogicTube

Dr. Jesper Eugen-Olsen talks on suPAR and Chronic inflammation

Tue, 16 Jul 2024 10:41:27 GMT

Dr Eugen-Olsen talks on chronic inflammation and how it is linked to the development of disease. The lecture is from the Longevity and Biohacking Conference in Andorra, July 2024 and is named "Cracking the longevity code: Measuring and mastering chronic inflammation"

The Save More study

Fri, 03 Dec 2021 10:22:15 GMT

suPAR can predict the need for mechanical ventilation and mortality in...

Fri, 24 Sep 2021 12:16:48 GMT

Jesper Eugen-Olsen presenting how suPAR can be used to predict patient outcomes in COVID-19 using suPAR. Read the full peer-reviewed publications: https://journals.sagepub.com/doi/full/10.1177/11772719211034685 ; https://www.researchsquare.com/article/rs-542503/v1 ; https://www.nature.com/articles/s41591-021-01499-z

Predicting patient outcomes in COVID-19

Fri, 24 Sep 2021 11:56:15 GMT

Jesper Eugen-Olsen presenting how suPAR can be used to predict patient outcomes in COVID-19 using suPAR. Read the full publication in Nature medicine here: https://www.nature.com/articles/s41591-021-01499-z

Prof. Peter Rossing on diabetes complications

Wed, 03 Jul 2019 12:53:40 GMT

Patients with type 1 diabetes are prone to develop complications such as kidney or heart disease. Professor Peter Rossing and his group are working on biomarkers that may predict which patients are in risk of developing these complications. Peter talks about their latest work on the risk biomarker suPAR and its predictive abilities. Their study "Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes" were published in Diabetes Care in 2019 (https://care.diabetesjournals.org/content/42/6/1112.long)

Interview with first author Viktor Curovic on his work on suPAR in diabetes...

Tue, 25 Jun 2019 14:28:33 GMT

interview on the following publication:

Diabetes Care. 2019 Jun;42(6):1112-1119. doi: 10.2337/dc18-1427. Epub 2019 Mar 18.
Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes.
Rotbain Curovic V1, Theilade S2, Winther SA2, Tofte N2, Eugen-Olsen J3, Persson F2, Hansen TW2, Jeppesen J4,5, Rossing P2,5.
Author information
Abstract
OBJECTIVE:
RESEARCH DESIGN AND METHODS:
RESULTS:
CONCLUSIONS:

Soluble urokinase plasminogen activator receptor (suPAR) is an important inflammatory biomarker implicated in endothelial and podocyte dysfunction. However, suPAR's predictive qualities for complications in type 1 diabetes have yet to be determined. We investigated the prognostic value of suPAR for the development of cardiovascular events, decline in renal function, and mortality in patients with type 1 diabetes.

We included 667 patients with type 1 diabetes with various degrees of albuminuria in a prospective study. End points were cardiovascular events (cardiovascular death, nonfatal acute myocardial infarction, nonfatal stroke, or coronary or peripheral arterial interventions), estimated glomerular filtration rate (eGFR) decline ≥30%, progression from lower to higher albuminuric state, development of end-stage renal disease (ESRD), and mortality. Follow-up was 5.2-6.2 years. Results were adjusted for known risk factors. Hazard ratios (HRs) are presented per doubling of suPAR with 95% CI. Relative integrated discrimination improvement (rIDI) was calculated.

Quantification of suPAR was available in all participants; median (interquartile range) was 3.4 ng/mL (2.7-4.5). The adjusted HR (95% CI) for cardiovascular events (n = 94), progression in albuminuria (n = 36), eGFR decline (n = 93), ESRD (n = 23), and mortality (n = 58) were 3.13 (1.96-5.45, P < 0.001), 1.27 (0.51-3.19, P = 0.61), 2.93 (1.68-5.11, P < 0.001), 2.82 (0.73-11.9, P = 0.13), and 4.13 (1.96-8.69, P < 0.001), respectively. rIDI was significant for cardiovascular events (22.6%, P < 0.001), eGFR decline (14.4%, P < 0.001), and mortality (23.9%, P < 0.001).

In patients with type 1 diabetes and a broad range of albuminuria, a higher level of suPAR is a significant and independent risk factor for cardiovascular events, decline in eGFR ≥30%, and mortality. In addition, suPAR contributes significantly to discrimination for the end points.

Dr. August Wrotek talks on suPAR as marker of severity of pneumonia in children

Fri, 13 Jun 2014 11:43:12 GMT

The 5th international suPAR symposium was held in Amsterdam 8 and 9th of May 2014. The symposium was entitled suPAR and its clinical use and focused on suPAR as a triage marker in the emergency room. The symposium was hosted by professor Marcus Schultz from the Amsterdam Medical Center. Dr. Wrotek's presentation was one of 25 lectures given over the 2-day 5'th International suPAR symposium. The programme and info on the conference can be found here: www.ViroGates.com

Dr. Rafal Wlazel talks on suPAR and prediction of AMI in pPCI patients

Fri, 13 Jun 2014 11:41:26 GMT

The 5th international suPAR symposium was held in Amsterdam 8 and 9th of May 2014. The symposium was entitled suPAR and its clinical use and focused on suPAR as a triage marker in the emergency room. The symposium was hosted by professor Marcus Schultz from the Amsterdam Medical Center. Dr. Wlazel's presentation was one of 25 lectures gicen over the 2-day Internationl suPAR symposium

Dr. Simone Theilade talks on suPAR as marker of diabetes complications

Fri, 13 Jun 2014 11:05:16 GMT

The 5th international suPAR symposium was held in Amsterdam 8 and 9th of May 2014. The symposium was entitled suPAR and its clinical use and focused on suPAR as a triage marker in the emergency room. The symposium was hosted by professor Marcus Schultz from the Amsterdam Medical Center. Dr. Theilade's presentation was one of 25 lectures given over the 2-day 5'th International suPAR symposium. The programme and info on the conference can be found here: www.ViroGates.com

suPAR and APACHE II score in risk assesment in critically ill patients by Dr...

Tue, 14 Aug 2012 11:58:51 GMT

Dr Evangelos Giamarellos-Bourboulis talks on the combined use of suPAR and APACHE II score in risk assesment in critically ill patients. The work by Giamarellos-Bourboulis and coworkes was published August 8th, 2012 in Critical Care and entitled "Risk assessment in sepsis: a new prognostication rule by APACHE II score and serum soluble urokinase plasminogen activator receptor" and can be read here http://ccforum.com/content/16/4/R149/abstract

Frank Tacke, MD, PhD, University Hopsital Achen, Germany: Diagnostic and...

Tue, 11 Oct 2011 12:48:22 GMT

Dr Tacke discuss suPAR results at the 2’nd International suPAR Symposium

Crit Care. 2011;15(1):R63. Epub 2011 Feb 16.
Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients.
Koch A, Voigt S, Kruschinski C, Sanson E, Dückers H, Horn A, Yagmur E, Zimmermann H, Trautwein C, Tacke F.
SourceDepartment of Medicine III, RWTH-University Hospital Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany.

Abstract
INTRODUCTION: suPAR is the soluble form of the urokinase plasminogen activator receptor (uPAR), which is expressed in various immunologically active cells. High suPAR serum concentrations are suggested to reflect the activation of the immune system in circumstances of inflammation and infection, and have been associated with increased mortality in different populations of non-intensive care patients. In this study we sequentially analyzed suPAR serum concentrations within the first week of intensive care in a large cohort of well characterized intensive care unit (ICU) patients, in order to investigate potential regulatory mechanisms and evaluate the prognostic significance in critically ill patients.

METHODS: A total of 273 patients (197 with sepsis, 76 without sepsis) were studied prospectively upon admission to the medical intensive care unit (ICU), on Day 3 and Day 7, and compared to 43 healthy controls. Clinical data, various laboratory parameters as well as investigational inflammatory cytokine profiles were assessed. Patients were followed for approximately one year.

RESULTS: Upon admission to the ICU suPAR serum concentrations were elevated in critically ill patients as compared with healthy controls. In sepsis patients suPAR levels were higher than in non-sepsis patients (with or without systemic inflammatory response syndrome (SIRS)). During the first week after admission to the ICU serum suPAR concentrations remained stably elevated. suPAR serum concentrations measured upon admission were closely and independently correlated to various laboratory parameters, specifically biomarkers of inflammation (tumor necrosis factor (TNF), C-reactive protein (CRP)), hepatic and renal dysfunction. High suPAR levels at admission and at Day 3 were a strong independent predictor for both ICU and long-term mortality in critically ill patients.

CONCLUSIONS: In sepsis and non-sepsis patients suPAR serum concentrations are increased upon admission to the ICU, likely reflecting the activation state of the immune system, and remain stably elevated in the initial course of treatment. Low suPAR levels are a positive predictor of ICU- and overall survival in critically ill patients, including sepsis and non-sepsis patients. Aside from its value as a promising new prognostic biomarker, both experimental and clinical studies are required in order to understand the specific effects and regulatory mechanisms of suPAR in SIRS and sepsis, and may reveal new therapeutic options.

Officel welcome words at the conference:
Dear Colleagues

On behalf of the scientific committee, it is my pleasure to welcome you to “The 2nd International Conference on suPAR” taking place in early spring 2011 at the Danish National Museum in Copenhagen.

The 1st International conference on suPAR” in 2003 shared findings on suPAR as a marker of disease progression and survival in HIV and TB infected. Since then, suPAR has been broadly applied to a range of diseases and the same picture is emerging. An elevated suPAR is associated with a negative prognosis independent of disease. Even among the general population, an elevated suPAR has recently been shown to be associated with increased risk of diseases such as cardiovascular disease, cancer and Type 2 Diabetes.

But what does an elevated suPAR reflect? The suPAR level is positively correlated with markers of inflammation and immune activation such as CRP (hsCRP), TNF-a and white blood cell counts. Thus, suPAR may be a novel marker of inflammation, and increased inflammation has in recent years been suggested as a disease driving mechanism. Nevertheless, suPAR remains associated with disease endpoints after the adjustment of other inflammatory markers and is less related to metabolic variables than CRP. Thus suPAR may reflect another aspect of inflammation than the classical markers do.

A large number of studies are currently investigating the role of suPAR in a wide variety of conditions, and this conference will bring forward the newest data which will further enlighten the role and possible applications of this biomarker.

We look forward to sharing these exciting data and to welcome you to the heart of Copenhagen

Sincerely

Jesper Eugen-Olsen, PhD, conference chairman
Laboratory research director,
Copenhagen University Hospital, Hvidovre

Purpose and Scope

The suPAR (soluble urokinase Plasminogen Activator Receptor) protein is a relatively new biomarker which has ability to predict severity of illness and mortality. The prognostic value of suPAR has been described in published studies in recent years and is currently being tested in several health care applications.

The symposium aim is to bring together researchers, users and other persons to discuss the features and potential usability of the suPAR protein as a biomarker and will:

◦Provide a forum to learn about new findings and current suPAR studies
◦Host a scientific community discussion on the new opportunities that exist with a prognostic biomarker
◦Hear from the delegates what questions, feed-back and ideas for suPAR applications and user requirements
◦Facilitate foundation for international net-working

suPAR - the inflammatory biomarker that provides unique prognostic evidence

Tue, 11 Oct 2011 11:13:18 GMT

A short movie on suPAR

To read more on suPAR, click here:
http://chronopause.com/index.php/2011/07/14/supar-power-a-rapid-inexpensive-highly-accurate-method-of-predicting-all-cause-and-disease-specific-mortality/

Or search www.pubmed.com using keyword suPAR

17-02-2020

Tue, 11 Oct 2011 09:13:18 GMT

A short movie on suPAR

To read more on suPAR, click here:

http://chronopause.com/index.php/2011/07/14/supar-power-a-rapid-inexpensive-highly-accurate-method-of-predicting-all-cause-and-disease-specific-mortality/

Or search www.pubmed.com using keyword suPAR

suPAR and HIV infection by Dr Ostrowski - Part 2

Fri, 30 Sep 2011 14:03:01 GMT

MD, PhD, DmSc Sisse Ostrowski gives insight into the inflammatory biomarker suPAR in HIV pathogenesis. Dr Ostrowski has published several papers in the field and gives and overview of the published data at the 2nd suPAR symposium in Copenhagen in 2011

Case stories for the ICU - suPAR and prognosis by Prof Paradowski

Fri, 30 Sep 2011 13:41:35 GMT

Professor Marek T Paradowski from Veterans Central University Hospital in Lodz, Poland, studies the kinetics and prognostic ability of the biomarkers Procalcitonin (PCT), C-reactive Protein (CRP) and soluble urokinase receptor (suPAR). The talk was given at the 2nd suPAR symposium in Copenhagen 2011.

suPAR and HIV infection by Dr Ostrowski - Part 1

Fri, 30 Sep 2011 13:36:27 GMT

2´nd International suPAR Symposium

Wed, 24 Aug 2011 11:49:48 GMT

2’nd International suPAR Symposium
The 2nd International Conference on suPAR” was taking place in early spring 2011 at the Danish National Museum in Copenhagen.

The 1st International conference on suPAR” in 2003 shared findings on suPAR as a marker of disease progression and survival in HIV and TB infected. Since then, suPAR has been broadly applied to a range of diseases and the same picture is emerging. An elevated suPAR is associated with a negative prognosis independent of disease. Even among the general population, an elevated suPAR has recently been shown to be associated with increased risk of diseases such as cardiovascular disease, cancer and Type 2 Diabetes.

The suPAR (soluble urokinase Plasminogen Activator Receptor) protein is a relatively new biomarker which has ability to predict severity of illness and mortality. The prognostic value of suPAR has been described in published studies in recent years and is currently being tested in several health care applications.

The symposium aim is to bring together researchers, users and other persons to discuss the features and potential usability of the suPAR protein as a biomarker and will:

◦ Provide a forum to learn about new findings and current suPAR studies
◦ Host a scientific community discussion on the new opportunities that exist with a prognostic biomarker
◦ Hear from the delegates what questions, feed-back and ideas for suPAR applications and user requirements
◦ Facilitate foundation for international net-working

Preliminary Agenda

◦ Session 1: suPAR and 10-year risk in the General Population
◦ Session 2: suPAR and Prognosis in Infectious Diseases
◦ Session 3: suPAR as a Risk Biomarker in the Intensive Care Unit
◦ Session 4: Decreasing suPAR Concentration – Impact on survival?
◦ Session 5: Is there a Role for suPAR in Disease Risk Management?
◦